[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-hyperplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-hyperplasia":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,80,112,134,156],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":5},"100565990","comparison-between-bipolar-transurethral-resection-of-the-prostate-and-moses-assisted-holmium-laser-enucleation-of-the-prostate-100565990",false,"NCT06649357","Comparison Between Bipolar Transurethral Resection of the Prostate and Moses Assisted Holmium Laser Enucleation of the Prostate","Comparison Between Bipolar Transurethral Resection of the Prostate and Moses Assisted Holmium Laser Enucleation of the Prostate. A Prospective Randomized Multicentric Study","Inclusion Criteria:\n\n* Patients with maximum flow rate \\\u003C 15 ml\u002Fsec before obstructive surgery or with maximum flow rate \\> 15 ml\u002Fsec and urodynamic study showing high-flow obstruction defined as bladder outlet obstruction index \\> 40.\n* Patients with moderate to severe lower urinary tract symptoms (LUTS) according to the International Prostate Symptom Score (IPSS). Score between 8 and 35.\n* Patients with a prostate volume between 40 and 80 cc, measured by urological ultrasound or MRI.\n\nExclusion Criteria:\n\n* History of prior prostatic obstructive or urethral surgery.\n* Diagnosis of prostate neoplasia.\n* Diagnosis of urothelial neoplasia.\n* Lack of flowmetry or IPSS data before surgery.\n* Diagnosis or suspicion of hypo\u002Facontractile detrusor before prostatic obstructive surgery.\n* Diagnosis or suspicion of neurogenic bladder or neurological disease.\n* History of pelvic radiation therapy.","MALE",{"count":18,"type":19},130,"ESTIMATED","INTERVENTIONAL",[22],"NA","Introduction: Multiple studies have demonstrated the superiority of HoLEP in aspects such as transfusión rates or postoperative stay. On the other hand, no differences have been observed in terms of functional outcomes between both techniques, and surgical times reported in different studies tend to be longer for HoLEP. These results likely contribute to TURP, especially with bipolar energy (Bi-TURP), continuing to be considered by many the gold standard for surgical treatment of BPH.\n\nSofware and hardware upgrades to the Lumenis Pulse 120H. system in 2017, delivered MOSES 2.0, a single-use laser fibre used to perform MOSES augmented HoLEP (MoLEP). MoLEP has shown to be superior in intraoperative outcomes when compared to traditional HoLEP. The availability of new morcellators might also decrease surgical time for HoLEP. This changing landscape for BPH endoscopic surgery deserves a re-evaluation of the differences between Bi-TURP and MoLEP.\n\nPrimary Objective: To compare the hospital stay of patients of patients undergoing MoLEP with those undergoing Bi-TURP.\n\nSecondary objectives:\n\n* To compare the surgical time of MoLEP with that of Bi-TURP.\n* To compare the bladder catheterization time aCer MoLEP with that of Bi-TURP.\n* To compare the postoperative complication rate patients undergoing MoLEP with those undergoing Bi-TURP.\n* To compare functional results of patients undergoing MoLEP with those undergoing Bi-TURP.\n\nThis study is a prospective multicentric randomized and controlled trial. The study compares two types of BPH surgery without changing standard medical practice.\n\nThe study will include patients who are candidates according to standard medical practice for BPH surgery. Patients will be randomized to one of two groups of treatment.\n\n* The MoLEP group will receive surgical treatment with MoLEP.\n* The Bi-TURP group will receive surgical treatment with Bi-TURP. Surgical technique and postoperative care will follow standard clinical practice at each participating centre.",[25,26,27],"Prostate Hyperplasia","Surgery","Endoscopic Anatomical Enucleation of the Prostate (EEAP)",[29,26,30],"Prostate hyperplasia","Endoscopic anatomical enucleation of the prostate (EEAP)","RECRUITING","2026-04-23",{"date":34,"type":35},"2026-04-29","ACTUAL",{"date":37,"type":35},"2025-04-01",{"date":39,"type":19},"2030-11",{"name":41,"class":42},"Fundacio Puigvert","OTHER",{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100580196","online-adaptive-stereotactic-body-radiotherapy-for-localized-prostate-cancer-x-smile-100580196","NCT06834152","Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer (X-SMILE)","Online Adaptive Stereotactic Body Radiotherapy for Localized Prostate Cancer in Patients With Lower Urinary Tract Symptoms and\u002For Prostate Hyperplasia (X-SMILE)","X-SMILE","Inclusion Criteria:\n\n* histologically confirmed localized prostate cancer\n* planned treatment is SBRT according to standard of care and consists of definitive CT or MRI online adaptive SBRT of the prostate according to the PACE trial which includes a total dose to clinical target volume 1 (CTV1, i.e. prostate and proximal 1 cm of the seminal vesicle) of 40.0 Gy in 5 weekly fractions (single dose of 8.0 Gy) and total dose to planning target volume 1 (PTV1) of 37.5 Gy in 5 weekly fractions (single dose of 7.5 Gy) with a compromise for bowel sparing allowed. For patients with unfavorable intermediate to very high-risk disease (according to NCCN guidelines) a total dose to the planning target volume 2 (PTV2, i.e. proximal 1-2 cm of the seminal vesicle) of 32.5 Gy in 5 weekly fractions (single dose of 6.5 Gy) will be delivered.\n* intermediate to (very) high risk localized prostate cancer (≤ cT3a and Gleason score ≤ 9 and\u002For PSA ≤ 20 ng\u002Fml)\n* prostate volume \\> 60 cc and\u002For IPSS \\> 12;\n\nExclusion Criteria:\n\n* Very high risk localized prostate cancer with indication for ADT and ARPI (i.e. Gleason ≥ 8 and cT3a)\n* Involvement of seminal vesicles (cT3b)\n* Contraindications against definitive CT or MRI-adaptive radiotherapy of the prostate, e.g. inflammatory bowel disease (IBD); previous radiotherapy in the pelvis, previous local radiotherapy of the prostate, contraindication for MRI or CT;\n* Patients with severe genitourinary symptoms (e.g. recent urinary retention ≥ grade 3 according CTCAE v.5.0);\n* Lymph node metastases or distant metastases (i.e. no localised prostate cancer);\n* Participation in a clinical trial which might influence the results of this project.","18 Years",{"count":53,"type":19},75,"OBSERVATIONAL","The aim of this phase II international multicenter study is to evaluate the safety, feasibility, and efficacy of CT or MRI-adaptive SBRT, delivered in five weekly fractions, in patients with newly diagnosed localized prostate cancer who have lower urinary tract symptoms and\u002For prostatic hyperplasia.",[57,58,25,59],"Localized Prostate Carcinoma","Prostate Cancer (Adenocarcinoma)","Lower Urinary Track Symptoms",[61,62,63,64,65,66,67,68,69],"radiotherapy","SBRT","MRI","CT","stereotactic radiotherapy","localized prostate cancer","lower urinary tract symptoms","prostate hyperplasia","prostate cancer","2026-02-04",{"date":72,"type":35},"2026-02-09",{"date":74,"type":35},"2024-03-01",{"date":76,"type":19},"2031-06-30",{"name":78,"class":42},"University of Zurich",3,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":20,"phases":89,"briefSummary":90,"conditions":91,"keywords":99,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100384647","5-alpha-reductase-2-as-a-marker-of-resistance-to-5ari-therapy-100384647","NCT04288427","5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy","Inclusion Criteria:\n\n* Male (physiological);\n* Age ≥ 50;\n* Eligible for treatment with 5ARI therapy;\n* Presence of lower urinary tract symptoms secondary to BPH;\n* Prostate size \\>40cc by digital rectal examination;\n* Absence of prostate nodule, tenderness or firmness;\n* Mildly elevated PSA's \\>1.5 ng\u002Fml and ≤ 40 ng\u002Fml;\n* Undergoing clinically indicated prostate biopsy for elevated prostate-specific antigen (PSA).\n\nExclusion Criteria:\n\n* Diagnosis of any prostatic malignancy or precancerous lesions (atypical glandular foci and prostatic intraepithelial neoplasia);\n* Treatment with 5ARI (Finasteride or Dutasteride) within six months of study enrollment;\n* Current urinary tract infection;\n* Previous pelvic radiation;\n* Previous treatment with demethylating drugs;\n* Diagnosis of multiple sclerosis, Alzheimer's, Parkinson's, neurological deficits in the judgment of the investigator;\n* Unable or unwilling to undergo MRI due to implants, claustrophobia, etc.","50 Years",{"count":88,"type":19},120,[22],"The study is being conducted to learn why some patients with Benign Prostatic Hyperplasia (BPH) do not respond to a commonly used treatment drug, Finasteride. The hope is to find ways to predict which patients will not respond to Finasteride so that, in the future, these patients can be identified prior to offering this treatment and they can be offered alternative treatment strategies in its place. The aim is to see if noninvasive techniques such as MRI can detect inflammation of the prostate to assist with early detection of those who will and who will not respond to Finasteride.",[92,25,93,94,95,96,97,98],"Benign Prostatic Hyperplasia","Prostate Disease","Prostate Hypertrophy","Prostate Pain","Lower Urinary Tract Symptoms","Urinary Obstruction","Urinary Tract Disease",[100,101],"Finasteride","5 Alpha Reductase","2025-10-27",{"date":104,"type":35},"2025-10-28",{"date":106,"type":35},"2020-09-25",{"date":108,"type":19},"2026-11-30",{"name":110,"class":42},"Beth Israel Deaconess Medical Center",1,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":11,"sex":16,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":20,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":111},"100582601","management-of-dysuria-and-irritative-symptoms-after-holep-a-prospective-study-evaluating-the-efficacy-of-alpha-blocker-therapy-100582601","NCT06865430","Management of Dysuria and Irritative Symptoms After HoLEP: a Prospective Study Evaluating the Efficacy of Alpha-Blocker Therapy","Inclusion Criteria:\n\nMen over 40 years old, under 85 years old, and HoLEP surgery\n\nExclusion Criteria:\n\nProstate cancer, patients with bladder stones, patients with a history of urethral stricture, patients with detrusor underactivity in urodynamics, those who have had prostate surgery before","40 Years","85 Years",{"count":121,"type":19},82,[22],"Holmium Laser Enucleation of the Prostate (HoLEP) is an increasingly popular endoscopic minimally invasive surgical technique for the treatment of benign prostatic hyperplasia (BPH). In the literature, the long-term efficacy and low complication rates of HoLEP have been highlighted in many studies. However, in the early postoperative period, particularly within the first three months, irritative symptoms are reported in 17-35% of cases (1-2).\n\nThe pathophysiology of postoperative irritative symptoms is not yet fully understood, but it has been suggested that these symptoms may be associated with urethral trauma, the mucosal healing process, and detrusor overactivity. These symptoms can significantly impact quality of life, reducing patient satisfaction. In particular, dysuria is a frequently encountered symptom after HoLEP, with considerable individual variability in its severity and duration.\n\nThe effectiveness of alpha-blockers in alleviating postoperative dysuria and irritative symptoms remains a topic of debate in the literature. Although prostate tissue is surgically removed, alpha-blockers may improve urinary flow and relieve symptoms associated with bladder outlet obstruction by reducing urethral smooth muscle tone (3). Studies on the use of alpha-blockers following transurethral resection of the prostate (TURP) have shown limited postoperative benefits (4). However, to the best of our knowledge, no study has specifically evaluated their use following HoLEP, an enucleation-based technique. Therefore, further studies are needed to assess the role of alpha-blockers in managing dysuria after HoLEP.\n\nThe aim of this study is to evaluate the effectiveness of alpha-blocker therapy in managing dysuria and other irritative symptoms following HoLEP. Additionally, the study seeks to determine the impact of this treatment on quality of life and patient satisfaction.",[25],"2025-03-19",{"date":127,"type":35},"2025-03-24",{"date":129,"type":35},"2025-03-04",{"date":131,"type":19},"2026-03-04",{"name":133,"class":42},"Ankara Training and Research Hospital",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":20,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":111},"100533315","prostate-single-port--laser-enucleation-comparison-trial-100533315","NCT06224218","Prostate Single Port & Laser Enucleation Comparison Trial","Randomized Controlled Trial Comparing Single Port Simple Prostatectomy and Laser Enucleation of the Prostate for Benign Prostatic Hyperplasia","Inclusion Criteria:\n\n* Patients diagnosed with symptomatic Benign Prostatic Hyperplasia (BPH) who fail conservative treatment with drug therapy are eligible for surgical intervention.\n\nExclusion Criteria:\n\n* Adults unable to consent Prisoners Cognitive impaired adults Coagulopathy","88 Years",{"count":143,"type":19},116,[22],"Surgical treatments for benign prostatic hyperplasia (BPH) are necessary when non-procedural approaches fail to alleviate lower urinary tract symptoms (LUTS) or bladder outlet obstruction (BOO). Open simple prostatectomy and laser enucleation are recommended for prostatic adenoma size greater than 80 ml. Minimally invasive approaches, such as robotic-assisted simple prostatectomy, have gained popularity due to their comparable outcomes with lower morbidity. The introduction of the da Vinci single-port (SP) robotic platform offers potential advantages, but its outcomes have not been thoroughly investigated.\n\nThis randomized controlled trial aims to compare the outcomes of SP simple prostatectomy performed using the da Vinci robotic platform versus thulium laser enucleation of the prostate for the treatment of BPH and BOO.",[25],"2024-05-13",{"date":149,"type":35},"2024-05-16",{"date":151,"type":35},"2024-01-15",{"date":153,"type":19},"2027-08-15",{"name":155,"class":42},"University of Illinois at Chicago",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":178},"100525062","prostate-metabolism-cancer-risk-and-gut-microbiota-100525062","NCT06116851","Prostate Metabolism, Cancer Risk and Gut Microbiota","PROMIC","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form.\n* Ability and stated willingness to comply with all study procedures and availability for the duration of the study.\n\nExclusion Criteria:\n\n* inability to comply with study procedures or unwillingness to participate in the study.",{"count":164,"type":19},300,"This is a prospective, single center translational multiple cohort study to investigate the association of gut microbiota and prostate cancer.",[167,25],"Prostate Cancer","2023-10-30",{"date":170,"type":35},"2023-11-03",{"date":172,"type":35},"2022-06-01",{"date":174,"type":19},"2026-09-15",{"name":176,"class":177},"Turku University Hospital","OTHER_GOV",2]